Nitrogen Mustard Therapy in Cutaneous Blastomatous Disease

Osborne, Earl D.; Jordon, James W.; Hoak, Frank C.; Pschierer, Francis J.

doi:10.1001/jama.1947.02890170001001

Cited by 58 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 1947, the rst use of cytotoxic therapy to treat systemic lupus erythematosus (SLE) was reported. 1 By 1986, the intramural NIH group showed monthly IV cyclophosphamide to be more effective than oral prednisone 2 or intravenous solumedrol 3 for diffuse proliferative glomerulonephritis. Future studies established the need for 2 years of additional quarterly cyclophosphamide maintenance to retain renal response.…”

Section: Introductionmentioning

confidence: 99%

High-dose cyclophosphamide for severe systemic lupus erythematosus

Gladstone

Prestrud²,

Pradhan³

et al. 2002

Lupus

View full text Add to dashboard Cite

Cytotoxic therapy is a cornerstone for patients with severe systemic lupus erythematosus (SLE). High-dose cyclophosphamide, 200 mg/kg, can induce a complete remission without the need for stem cell rescue in patients with autoimmune illnesses. Here we report on our first four patients treated for severe SLE with this treatment approach. Patients received cyclophosphamide, 200 mg/kg, divided over 4 days. Starting day 10, patients received filgrastim, 5 micrograms/kg/day, until their absolute neutrophil count (ANC) rose to 10.0 x 10(9)/l for two consecutive days. Disease activity as evaluated by scores from the Systemic Lupus Activity Measure-2, the SLE Disease Activity Index and the Responder Index for Lupus Erythematosus were completed before and after high-dose therapy. Before high-dose cyclophosphamide, SLE disease duration ranged from 8 to 21 (mean 12.5) years. Their average disease activity measured by SLAM-2 and SLEDAI was 15.5 (range 11-19) and 23.25 (range 20-26), respectively. At a median of 22 (range 12-39) months of follow-up, mean disease activity measured by SLAM-2 and SLEDAI decreased to 6.25 and 7.75, respectively. All patients experienced febrile neutropenia. No long-term morbidities or mortalities were observed. High dose cyclophosphamide is a therapy capable of decreasing disease severity in poor prognosis SLE patients. Future study is warranted for both refractory patients as well as primary therapy for patients with moderate to severe disease presentations.

show abstract

Section: Introductionmentioning

confidence: 99%

High-dose cyclophosphamide for severe systemic lupus erythematosus

Gladstone

Prestrud²,

Pradhan³

et al. 2002

Lupus

View full text Add to dashboard Cite

show abstract

“…The first paper reporting this research was published in 1946 (21) 2 , after which the use of nitrogen mustard in the treatment of hematologic disease became more widespread. As we have already seen, a nitrogen mustard, mecloretamin, was used experimentally in SLE in 1947 (7), in rheumatoid arthritis in 1951 (9), and later in other connective tissue and vascular diseases. Attempts were made to obtain a compound with less general toxicity using a prodrug (22), and this led, in 1958, to the synthesis of cyclophosphamide in the laboratories of the Asta Werke AG, thanks to the work of Herbert Arnold, Friedrich Bourseaux and Norbert Brock (23).…”

mentioning

confidence: 98%

“…However, very soon, in the mid-twentieth century, the first attempts were made to use these drugs as therapy for rheumatic disease. In 1947, in the United States, a team of dermatologists led by Earl D. Osborne (7), proposed the use of nitrogen mustard in the therapy of systemic lupus erythematosus (SLE). In 1951, Richard Gubner and his co-workers (8) proposed the use of aminopterin, and Carlos Jiménez-Díaz (9) proposed the use of nitrogen mustard in the treatment of rheumatoid arthritis (RA).…”

mentioning

confidence: 99%

Short story of antirheumatic therapy.VIII. The immunodepressants

Pasero¹,

Marson²

2012

Reumatismo

View full text Add to dashboard Cite

The use of immunosuppressive drugs in rheumatology is fairly recent, starting just after the Second World War with the introduction of the first alkylating agents in oncohematology. When it became clear that some rheumatic diseases, particularly rheumatoid arthritis and systemic lupus erythematosus, showed an immune-mediated pathogenesis, including proliferation of immunocompetent cells, an application was soon found for immunosuppressive drugs in their treatment. This review outlines the historical milestones that led to the current use of drugs belonging to the major groups of immunosuppressants, i.e. alkylating agents (cyclophosphamide), folic acid (methotrexate) and purine (azathioprine) antagonists. We will also talk about the history of cyclosporin A, the first "selective" immunosuppressive agent, and that of some immunoactive drugs used more recently in rheumatology, such as mycophenolate mofetil, dapson and thalidomide, is briefly described.

show abstract

“…Osborne и соавт. [24] опубликовали первое сообщение об эффективности nitrogen mustard (аналог азотистого иприта с алкилирующим механизмом действия) у 4 пациентов, среди которых у одного была диссеминированная красная волчанка. Фактически эта работа послужила началом новому направлению терапии СКВ с применением цитостатических препаратов.…”

unclassified

Systemic lupus erythematosus: history and modernity

Насонов

Soloviev²,

Arshinov

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a systemic autoimmune rheumatic disease of unknown etiology, characterized by hyperproduction of non-organ-specific autoantibodies to various components of the cell nucleus and the development of immune-inflammatory damage to internal organs. Currently, SLE is considered as a prototype of a systemic human autoimmune pathology, the central mechanism of immunopathogenesis of which is a violation of immunological tolerance to self-antigens, due to a complex interaction of genetic, epigenetic, environmental factors. The publication discusses the history of the study of SLE, the contribution of Russian scientists (V.A. Nasonova and others) to the study of th is problem, current trends in clinical and scientific research related to the improvement of diagnostic criteria and pharmacotherapy of this disease.

show abstract

Nitrogen Mustard Therapy in Cutaneous Blastomatous Disease

Cited by 58 publications

References 2 publications

High-dose cyclophosphamide for severe systemic lupus erythematosus

High-dose cyclophosphamide for severe systemic lupus erythematosus

Short story of antirheumatic therapy.VIII. The immunodepressants

Systemic lupus erythematosus: history and modernity

Contact Info

Product

Resources

About